Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Radiographics ; 40(2): 306-325, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32031911

RESUMEN

In addition to the well-characterized BRCA1 and BRCA2 hereditary breast and ovarian cancer syndromes, many other syndromes that are associated with genetic mutations predispose individuals to an increased risk of breast and gynecologic malignancies. Many mutated genes encode for tumor-suppressor products and are inherited in an autosomal dominant manner. Mutations markedly increase an individual's lifetime risk of cancers in different organ systems, depending on the associated syndrome. These syndromes include Lynch syndrome, the most common hereditary cause of endometrial cancer, and Peutz-Jeghers syndrome, which increases the risks of breast cancer, ovarian cancer, and cervical adenoma malignum. Li-Fraumeni syndrome and Cowden syndrome increase the risk of breast cancer, and Gorlin syndrome increases the risk of ovarian fibromas. With advances in genetic testing, clinicians' knowledge and awareness of the numerous additional genes associated with breast and ovarian cancers, such as ATM, CHEK2, and PALB2, are rapidly expanding. Radiologists have essential roles in patient management, which include developing optimal screening protocols for these patients and closely monitoring them for the development or recurrence of disease-specific malignancies. Radiologists' roles continue to increase and evolve as more mutations are identified and high-risk imaging screening recommendations expand to identify these patients. Understanding the epidemiologic, genetic, and pathophysiologic features and the cancers associated with these syndromes enables radiologists to appropriately contribute to patient management, ensure accurate and timely diagnosis, and make syndrome-specific imaging recommendations. ©RSNA, 2020.


Asunto(s)
Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/genética , Neoplasias de los Genitales Femeninos/diagnóstico por imagen , Neoplasias de los Genitales Femeninos/genética , Síndromes Neoplásicos Hereditarios/diagnóstico por imagen , Femenino , Genes BRCA1 , Genes BRCA2 , Predisposición Genética a la Enfermedad , Humanos
2.
J Breast Imaging ; 4(2): 168-176, 2022 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-38422427

RESUMEN

OBJECTIVE: To assess whether changes in quantitative parameters on breast MRI better predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer than change in volume. METHODS: This IRB-approved retrospective study included women with newly diagnosed breast cancer who underwent 3T MRI before and during NAC from January 2013 to December 2019 and underwent surgery at our institution. Clinical data such as age, histologic diagnosis and grade, biomarker status, clinical stage, maximum index cancer dimension and volume, and surgical pathology (presence or absence of in-breast pCR) were collected. Quantitative parameters were calculated using software. Correlations between clinical features and MRI quantitative measures in pCR and non-pCR groups were assessed using univariate and multivariate logistic regression. RESULTS: A total of 182 women with a mean age of 52 years (range, 26-79 years) and 187 cancers were included. Approximately 45% (85/182) of women had pCR at surgery. Stepwise multivariate regression analysis showed statistical significance for changes in quantitative parameters (increase in time to peak and decreases in peak enhancement, wash out, and Kep [efflux rate constant]) for predicting pCR. These variables in combination predicted pCR with 81.2% accuracy and an area under the curve (AUC) of 0.878. The AUCs of change in index cancer volume and maximum dimension were 0.767 and 0.613, respectively. CONCLUSION: Absolute changes in quantitative MRI parameters between pre-NAC MRI and intra-NAC MRI could help predict pCR with excellent accuracy, which was greater than changes in index cancer volume and maximum dimension.

3.
Semin Musculoskelet Radiol ; 11(2): 192-8, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18095250

RESUMEN

Ultrasound is a nonionizing, low-cost, portable imaging technique for the evaluation of tendons, muscles, joints, soft tissue masses, and cysts, especially in patients unable to tolerate computed tomography or magnetic resonance imaging. These advantages make ultrasound an ideal modality for guiding musculoskeletal interventions. Its real-time capabilities allow continuous observation of needle placement into the targeted area and direct visualization of interventions such as injection of medication while avoiding other soft tissue structures or nearby neurovascular bundles. After a brief overview of the technical factors involved in performing ultrasound-guided musculoskeletal interventions, this article reviews commonly performed percutaneous procedures in the musculoskeletal system.


Asunto(s)
Enfermedades Musculoesqueléticas/diagnóstico por imagen , Sistema Musculoesquelético/diagnóstico por imagen , Ultrasonografía Intervencional/métodos , Biopsia con Aguja , Calcinosis/diagnóstico por imagen , Femenino , Humanos , Masculino , Sistema Musculoesquelético/patología , Tendinopatía/diagnóstico por imagen
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA